Vegazo García O, Llisterri Caro J L, Jiménez Jiménez F J, Aznar Vicente J, Vicente Lozano J, Estiarte Navarro R
Departamento Médico. AstraZéneca Farmacéutica Spain, S.A. Madrid. España.
Aten Primaria. 2003 Feb 28;31(3):163-9. doi: 10.1016/s0212-6567(03)70677-5.
To evaluate the effectiveness of the fixed dose of a lisinopril-hydrochlorothiazide combination treatment in the control of blood pressure, in poorly controlled high blood pressure people, treated with monotherapy.Design. Prospective observational study.Setting. Primary care frame.Participants. 931 patients (56.7% women) with an average age of 62.0+/-3 years, were included by 199 primary care physicians. 915 patients (98%) ended the study and finally they were included for the statistical analysis.
OMS/SIH recommendations on blood pressure measurement and diagnose of poor control were followed. Pulse pressure, body mass index and basic clinical analyses were assessed. Four continuation visits were made during six months.
Lisinopril-hidrochlorothiazide (20/12.5 mg) reduced significantly SBP (24.6 +/- 3.5 mm Hg) and DBP (14,3 +/- 0.7 mm Hg) (P<.001). Blood pressure control was only influenced by age (OR, 0.81; 95% CI, 0.71-0.92; P=.001). Pulse pressure was reduced in 10.4 +/- 4.3 mm Hg (P<.001). After 24 weeks of treatment, glycemic and lipidic profiles showed an improvement, as well as HbA1c in diabetic people.
In Primary care, a 52.8% of poorly controlled with monotherapy high blood pressure people were controlled by a combination of lisinopril-hydrochlorothiazide (20/12.5 mg). In addition, pulse pressure was decreased and both lipid and glucose blood profiles improved.